Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Instrumentation
Thermo Fisher buys diagnostics firm Binding Site Group
by Craig Bettenhausen
November 3, 2022
| A version of this story appeared in
Volume 100, Issue 39
Thermo Fisher Scientific has agreed to purchase the specialty diagnostic firm Binding Site for $2.6 billion. The company, which is currently owned by the private equity firm Nordic Capital, makes assays and instruments for diagnosing and measuring immune disorders and blood cancers. Its flagship product serves people with multiple myeloma. Binding Site says it expects income of $220 million in 2022 and employs 1,100 workers worldwide. The firms expect the deal to close in the first half of 2023.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter